Cite
HARVARD Citation
Santucci, J. et al. (2022). Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. European journal of cancer. pp. 102-112. [Online].